Skip to main content

Advertisement

SpringerLink
Log in

Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Antiangiogenic treatment has recently become an integral part of modern cancer therapy targeting the vasculature of numerous aggressive malignancies including glioblastoma. There is preclinical evidence that antiangiogenic therapies promote glioma cell invasiveness. In clinical series, upon progression on antiangiogenic therapy with the vascular endothelial growth factor–directed antibody bevacizumab (BEV), glioblastoma has been reported to display a more infiltrative pattern of recurrence. This distant spread at recurrence or progression and a gliomatosis cerebri-like growth pattern is best detectable on fluid-attenuated inversion recovery MRI. The frequency of up to 20% to 30% of such a pattern in BEV-treated patients is higher than expected to occur without BEV. Older reports and common clinical knowledge estimate the frequency of diffuse or distant spread in recurrent glioblastoma at 10%. This observation stimulated two streams of research. One is to overcome this often insidious adverse effect of antiangiogenic treatment, to optimize antiangiogenic therapies and to face this major challenge, integrating antiangiogenic with anti-invasive mechanisms into one combined treatment concept. The second is questioning a specific property of antiangiogenic therapy to induce diffuse or distant spread. Here, alternative hypotheses of increased awareness and better imaging as well as invasiveness being part of the natural course of the disease have been tested. Without doubt, migration and invasiveness are major obstacles to successful glioma therapy, notably local therapies, both in the natural course of the disease and in the concept of “evasive resistance.” However, clinical analyses of case series, matched pairs analyses, and follow-up on the BRAIN trial (A Study to Evaluate Bevacizumab Alone or in Combination with Irinotecan for Treatment of Glioblastoma Multiforme), which led to accelerated approval of BEV for recurrent glioblastoma in the United States, have not supported a specific propensity of BEV to induce diffuse growth or distant spread at recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Friedman HS, Prados MD, Wen PY, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733–40. This is the final report of the BRAIN trial, which represents the major clinical data leading to approval of BEV for recurrent glioblastoma in several countries outside the European Union.

    Article  PubMed  CAS  Google Scholar 

  2. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5.

    Article  PubMed  CAS  Google Scholar 

  3. • Wick W, Weller M, van den Bent M, Stupp R: Avastin and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010, 28:188–90. This is a critical letter summarizing the European perspective on the approval of BEV.

    Article  Google Scholar 

  4. Summary Minutes of the Oncologic Drugs Advisory Committee March 31, 2009. In: Center for Drug Evaluation and Research ed. Washington: Food and Drug Administration 2009

  5. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.

    Article  PubMed  CAS  Google Scholar 

  6. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553–63.

    PubMed  CAS  Google Scholar 

  7. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–9.

    Article  PubMed  CAS  Google Scholar 

  8. •• Kamoun WS, Ley CD, Farrar CT, et al.: Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009, 27:2542–52. This is an interesting preclinical work providing evidence for one of the main mechanisms by which antiangiogenesis is beneficial in brain tumors (ie, brain pressure control).

    Article  PubMed  CAS  Google Scholar 

  9. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.

    PubMed  CAS  Google Scholar 

  10. • Wen PY, Macdonald DR, Reardon DM, et al.: Draft proposal for an updated response assessment criteria for high grade gliomas, response assessment in neuro-oncology (RANO) working group. J Clin Oncol 2010, 28:1963–72. This is a task force report on an update of the imaging criteria for the evaluation of brain tumors.

    Article  PubMed  Google Scholar 

  11. Norden AD, Drappatz J, Muzikansky A, et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009;92:149–55.

    Article  PubMed  CAS  Google Scholar 

  12. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299–309.

    Article  PubMed  CAS  Google Scholar 

  13. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2:306–14.

    Article  PubMed  CAS  Google Scholar 

  14. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61:6624–8.

    PubMed  CAS  Google Scholar 

  15. •• Pàez-Ribes M, Allen E, Hudock J, et al.: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220–31. This is an authoritative preclinical paper on evasive resistance in cancer.

    Article  PubMed  CAS  Google Scholar 

  16. Lee DF, Hung MC. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle. 2007;6:3011–4.

    Article  PubMed  CAS  Google Scholar 

  17. Wild-Bode C, Weller M. Rimner A:Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 2001;61:2744–50.

    PubMed  CAS  Google Scholar 

  18. Wick W, Wick A, Schulz JB. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res. 2002;62:1915–9.

    PubMed  CAS  Google Scholar 

  19. Narayana A, Kelly P, Golfinos JG, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110:173–80.

    Article  PubMed  Google Scholar 

  20. • Norden AD, Young GS, Setayesh K, et al.: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779–87. This is the first structured report on the hypothesis of BEV, although some clinical efficacy enhances diffuse and distant progression patterns in glioblastoma.

    Article  PubMed  CAS  Google Scholar 

  21. Iwama T, Yamada H, Sakai N, et al. Correlation between magnetic resonance imaging and histopathology of intracranial glioma. Neurol Res. 1991;13:48–54.

    PubMed  CAS  Google Scholar 

  22. Rieger J, Bähr O, Müller K. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol. 2010;99:49–55.

    Article  PubMed  CAS  Google Scholar 

  23. Verhoeff JJC, van Tellingen O, Claes A, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 2009;9:444.

    Article  PubMed  Google Scholar 

  24. • Wick W, Stupp R, Beule A-C, et al.: A novel tool to analyse MRI recurrence patterns in glioblastoma. Neuro Oncol 2008, 10:1019–24. This discusses the development of a tool for the groupwise analysis of recurrence patterns in brain tumors. No evidence for a differential recurrence pattern in radiotherapy- versus radiotherapy plus temozolomide-treated patients is found.

    Article  PubMed  Google Scholar 

  25. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2010;28:e91–3.

    Article  PubMed  Google Scholar 

  26. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73:1200–6.

    Article  PubMed  CAS  Google Scholar 

  27. Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer. 2009;124:2719–27.

    Article  PubMed  CAS  Google Scholar 

  28. Maurer GD, Tritschler I, Adams B, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol. 2009;11:747–56.

    Article  PubMed  CAS  Google Scholar 

  29. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15:392–400.

    Article  PubMed  CAS  Google Scholar 

  30. Weller M, Reardon D, Nabors B, et al. Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med. 2009;15:726.

    Article  PubMed  CAS  Google Scholar 

  31. Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res. 2008;14:5941–6.

    Article  PubMed  CAS  Google Scholar 

  32. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 2007;13:6735–42.

    Article  PubMed  CAS  Google Scholar 

  33. Reardon D, Cloughesy T, Raizer J, et al. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008;26(Suppl 15s):101s. abstract 2051.

    Google Scholar 

  34. Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol. 2009;27:4155–61.

    Article  PubMed  CAS  Google Scholar 

  35. Iwamoto FM, Kreisl TN, Kim L, et al. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer. 2010;116:1776–82.

    Article  PubMed  CAS  Google Scholar 

  36. Kleber S, Sancho-Martinez I, Wiestler B, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell. 2008;13:235–48.

    Article  PubMed  CAS  Google Scholar 

  37. Pfenning P-N, Weiler M, Thiepold A-L, et al.: Novel antiinvasive and antiangiogenic mechanisms of mTOR inhibition in glioblastoma. Proceedings of the American Association for Cancer Research 101st Annual Meeting April 2010, Washington D.C./USA (abstract 1308).

  38. Chamberlain MC, Lassman AB, Iwamoto FM. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2010;74:1239–41.

    Article  PubMed  Google Scholar 

  39. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol. 2011;101:319–23.

    Article  PubMed  Google Scholar 

  40. •• Wick A, Dörner N, Schäfer N, et al.: Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol in press. This is the first controlled data set demonstrating that distant and diffuse recurrence is more associated with the malignant phenotype of glioblastoma than to anatiangiogenic treatments.

  41. Hamstra DA, Galbán CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26:3387–94.

    Article  PubMed  Google Scholar 

  42. Sadeghi N, Camby I, Goldman S, et al. Effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas: preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level. Am J Roentgenol. 2003;181:235–41.

    Google Scholar 

  43. Wick W, Puduvalli VK, Chamberlain M, et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma: a phase III study. J Clin Oncol. 2010;28:1168–74.

    Article  PubMed  CAS  Google Scholar 

  44. Batchelor TT, Mulholland P, Neyns B, et al.: A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. ESMO 2010, LBA 7.

  45. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7:1152–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Images in Figures 1 and 2 are courtesy of the Department of Neuroradiology, University Clinic Heidelberg (Chairman: Prof. Dr. Martin Bendszus). For A. Wick, this work was supported by the Hertie Foundation and the Olympia Morata Program of the Medical Faculty in Heidelberg.

Disclosure

Conflicts of interest: W. Wick: Advisory Boards for Astra Zeneca, BMS, MSD, Merck, Pfizer, Roche/Genentech, and Schering-Plough; Speakers honoraria from Merck, Roche, Schering-Plough, and Wyeth/Pfizer; and unrestricted research funding from Eli Lilly and Schering-Plough for projects unrelated to the current manuscript; A. Wick: none; M. Weiler: none; M. Weller: Advisory Boards for Astra Zeneca, Bayer Schering, BMS, MSD, Merck, Miltenyi Biotech, Roche/Genentech, and Schering-Plough; Speakers honoraria from Merck, Roche, and Schering-Plough; and unrestricted research funding from Merck, MSD, and Roche for projects unrelated to the current manuscript.

Author information

Authors and Affiliations

  1. Department of Neurooncology, University Clinic Heidelberg, Heidelberg, Germany

    Wolfgang Wick, Antje Wick & Markus Weiler

  2. Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany

    Wolfgang Wick & Markus Weiler

  3. Department of Neurology, University Hospital Zurich, Zurich, Switzerland

    Michael Weller

  4. Department of Neurooncology, Neurology Clinic and National Center for Tumor Diseases, University of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany

    Wolfgang Wick

Authors
  1. Wolfgang Wick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antje Wick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markus Weiler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Wick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wick, W., Wick, A., Weiler, M. et al. Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence. Curr Neurol Neurosci Rep 11, 305–312 (2011). https://doi.org/10.1007/s11910-011-0184-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-011-0184-0

Keywords

Search

Navigation